• Home
  • Search Results
  • Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids.

Probing the Global Cellular Responses to Lipotoxicity Caused by Saturated Fatty Acids.

Molecular cell (2019-03-09)
Manuele Piccolis, Laura M Bond, Martin Kampmann, Pamela Pulimeno, Chandramohan Chitraju, Christina B K Jayson, Laura P Vaites, Sebastian Boland, Zon Weng Lai, Katlyn R Gabriel, Shane D Elliott, Joao A Paulo, J Wade Harper, Jonathan S Weissman, Tobias C Walther, Robert V Farese

Excessive levels of saturated fatty acids are toxic to cells, although the basis for this lipotoxicity remains incompletely understood. Here, we analyzed the transcriptome, lipidome, and genetic interactions of human leukemia cells exposed to palmitate. Palmitate treatment increased saturated glycerolipids, accompanied by a transcriptional stress response, including upregulation of the endoplasmic reticulum (ER) stress response. A comprehensive genome-wide short hairpin RNA (shRNA) screen identified >350 genes modulating lipotoxicity. Among previously unknown genetic modifiers of lipotoxicity, depletion of RNF213, a putative ubiquitin ligase mutated in Moyamoya vascular disease, protected cells from lipotoxicity. On a broader level, integration of our comprehensive datasets revealed that changes in di-saturated glycerolipids, but not other lipid classes, are central to lipotoxicity in this model. Consistent with this, inhibition of ER-localized glycerol-3-phosphate acyltransferase activity protected from all aspects of lipotoxicity. Identification of genes modulating the response to saturated fatty acids may reveal novel therapeutic strategies for treating metabolic diseases linked to lipotoxicity.

Product Number
Product Description

β-Nicotinamide adenine dinucleotide, reduced disodium salt hydrate, ≥97% (HPLC)
Thapsigargin, ≥98% (HPLC), solid film
Myriocin from Mycelia sterilia, ≥98% (HPLC), powder
1,2-Dioleoyl-sn-glycerol, ≥97%
Stearoyl coenzyme A lithium salt, ≥90%
1,2-Dipalmitoyl-sn-glycerol, ≥99%
LDN-57444, ≥98% (HPLC)
MISSION® esiRNA, targeting human RNF213 (1)